supported by grants from the National Key R&D Program of China(2017YFA0105803);the National Natural Science Foundation of China(82270886,82070811);the Science and Technology Plan Project of Guangzhou City(202007040003,202201020497);the 5010 Clinical Research Projects of Sun Yat-Sen University(2015015);the Dengfeng Plan High-level Hospital Construction Opening Project of Foshan Fourth People's Hospital(FSSYKF-2020011 and FSSYKF-2020009)。
In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount...